医药生物行业：MNC账上还有多少钱？还有啥可能布局？【创新药大牛市】分支思路（一）中国超市更新

医药生物行业：IBD治疗领域存在未满足的需求，关注新靶点、新机制－创新药盘点系列报告

医药生物行业：2025ASCO大会国内重点研究总结报告

中国诸多创新药资产近年来逐步进入全球视野，临床数据在各类学术会议上占据越发重要的地位，BD授权金额及数 量持续攀升，全球影响力持续扩大。伴随着临床数据的驱动以及持续强化的BD预期的催化，创新药板块在25H1迎来一轮估值的修复，越来越多中国资产的全球价值开始获得认同。信达生物核心肿瘤管线资产IBI363（PD1/IL2α）在实体瘤上有望实现“热” 肿瘤超越+“冷”肿瘤突破，具备超重磅炸弹潜力。康方生物作为全球双抗引领者，其核心产品依沃西（AK112，PD-1/VEGF双 抗）成为全球首个在1L肺癌治疗中mPFS超越K药的双抗，具有成为新一代IO基石药物的巨大潜力。

Global Adeno-Associated Virus (AAV) CDMO Market Size and Share Analysis - Growth, Trends and Forecas...

The market by value in this report is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography. • Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

创新药和新消费交易拥挤度如何

癫痫药物行业：赛道百花齐放，潜力靶点或迎新突破－深度报告

2025 年 1-6 月，面对外部环境急剧变化、内部风险挑战增多的复杂形势，宏观政策组合持续发力，工业经济总体平稳向好，但部分行业仍面临较大压力。在此形势下，医药行业主要运行指标呈现以下特点：一是行业固定资产投资额同比下降 3.0%；二是医药行业工业增加值保持增长，同比增长 1.3%；三是行业零售额继续保持增长，同比增长 1.4%；四是行业营业收入和行业利润总额均呈负增长，分别为同比下降 1.2% 和 2.8%。

Female sexual dysfunction treatment encompasses a variety of approaches aimed at addressing issues that prevent women from experiencing satisfying sexual activity. These treatments can be tailored to the specific type of dysfunction and its underlying causes, which may be physical, psychological, or a combination of both.